Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Recent studies have shown that withdrawing aspirin and maintaining P2Y12 inhibitor
monotherapy for up to 12 months post-PCI, after a brief period of DAPT, reduces bleeding
without increasing ischemic harm. Such effects have shown to of particular benefit in
patients with diabetes mellitus (DM). However, if an aspirin-free approach can be considered
after this time frame is a matter of debate. The aim of this study is to assess the PD
effects of ticagrelor 60 mg with and without aspirin therapy in CAD patients and to compare
this with a standard DAPT regimen of aspirin plus clopidogrel.